Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer

P Bharathiraja, P Yadav, A Sajid, SV Ambudkar… - Drug Resistance …, 2023 - Elsevier
ATP-binding cassette (ABC) transporters such as ABCB1, ABCG2, and ABCC1 are the
major players in drug efflux-mediated multidrug resistance (MDR), which severely affects the …

Vorinostat (SAHA) and breast cancer: an overview

A Wawruszak, L Borkiewicz, E Okon, W Kukula-Koch… - Cancers, 2021 - mdpi.com
Simple Summary Breast cancer (BC) is the most frequent malignancy diagnosed in 2020
worldwide. Despite significant advances in BC therapy, its pathogenesis is still not fully …

[HTML][HTML] Molecular mechanisms underlying the clinical efficacy of panobinostat involve Stochasticity of epigenetic signaling, sensitization to anticancer drugs, and …

N El Omari, S Bakrim, A Khalid, AN Abdalla… - Biomedicine & …, 2023 - Elsevier
Panobinostat, also known as Farydak®, LBH589, PNB, or panobinostat lactate, is a
hydroxamic acid that has been approved by the Food and Drug Administration (FDA) for its …

[HTML][HTML] HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer

B Biersack, B Nitzsche, M Höpfner - Cancer Drug Resistance, 2022 - ncbi.nlm.nih.gov
Epigenetic mechanisms play an important role in the development and persistence of
cancer, and histone deacetylase (HDAC) inhibitors are promising anticancer drugs targeting …

Selective inhibition of HDAC6 promotes bladder cancer radiosensitization and mitigates the radiation-induced CXCL1 signalling

YC Tsai, TY Wang, CL Hsu, WC Lin, JY Chen… - British Journal of …, 2023 - nature.com
Background Although trimodality therapy resecting tumours followed by chemoradiotherapy
is emerged for muscle-invasive bladder cancer (MIBC), chemotherapy produces toxicities …

In Vitro Drug Repurposing: Focus on Vasodilators

E Ribeiro, B Costa, F Vasques-Nóvoa, N Vale - Cells, 2023 - mdpi.com
Drug repurposing aims to identify new therapeutic uses for drugs that have already been
approved for other conditions. This approach can save time and resources compared to …

Downregulation of m6A writer complex member METTL14 in bladder urothelial carcinoma suppresses tumor aggressiveness

C Guimarães‐Teixeira, J Lobo… - Molecular …, 2022 - Wiley Online Library
N6‐methyladenosine (m6A) and its regulatory proteins have been associated with
tumorigenesis in several cancer types. However, knowledge on the mechanistic network …

[HTML][HTML] From Therapy Resistance to targeted therapies in prostate Cancer

F Moreira-Silva, R Henrique, C Jerónimo - Frontiers in Oncology, 2022 - frontiersin.org
Prostate cancer (PCa) is the second most common malignancy among men worldwide.
Although early-stage disease is curable, advanced stage PCa is mostly incurable and …

From HDAC to Voltage-Gated Ion Channels: What's Next? The Long Road of Antiepileptic Drugs Repositioning in Cancer

M Pellegrino, E Ricci, R Ceraldi, A Nigro, D Bonofiglio… - Cancers, 2022 - mdpi.com
Simple Summary Although in the last decades the clinical outcome of cancer patients
considerably improved, the major drawbacks still associated with chemotherapy are the …

Promoter Demethylation Upregulates STEAP1 Gene Expression in Human Prostate Cancer: In Vitro and In Silico Analysis

SM Rocha, I Sousa, IM Gomes, P Arinto… - Life, 2021 - mdpi.com
The Six Transmembrane Epithelial Antigen of the Prostate (STEAP1) is an oncogene
overexpressed in several human tumors, particularly in prostate cancer (PCa). However, the …